IRON Insider Trading
Insider Ownership Percentage: 4.24%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $22,156,241.87
Disc Medicine Insider Trading History Chart
This chart shows the insider buying and selling history at Disc Medicine by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Disc Medicine Share Price & Price History
Current Price: $52.41
Price Change: ▼ Price Decrease of -1.52 (-2.82%)
As of 03/13/2025 05:00 PM ET
Disc Medicine Insider Trading History
Disc Medicine Institutional Trading History
Data available starting January 2016
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Read More on Disc Medicine
Today's Range
Now: $52.41
52 Week Range
Now: $52.41
Volume
263,058 shs
Average Volume
359,832 shs
Market Capitalization
$1.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.73
Who are the company insiders with the largest holdings of Disc Medicine?
Disc Medicine's top insider shareholders include:
- Venture Fund X LP Atlas (Major Shareholder)
- Holdings A/S Novo (Major Shareholder)
- Kevin Bitterman (Director)
- Orbimed Advisors Llc (Director)
- Mona Ashiya (Director)
- John D Quisel (CEO)
- Jean M Franchi (CFO)
- Pamela Stephenson (Insider)
- Jonathan Yen-Wen Yu (COO)
- William Jacob Savage (Insider)
- Rahul Khara (Insider)
- Brian Richard Macdonald (Insider)
- Joanne Bryce (CFO)
- Rahul Khara (General Counsel)
- William Richard White (Director)
Learn More about top insider investors at Disc Medicine.
Who are the major institutional investors of Disc Medicine?
Which institutional investors are selling Disc Medicine stock?
In the previous quarter, IRON stock was sold by these institutional investors:
- Bain Capital Life Sciences Investors LLC
- Point72 Asset Management L.P.
- Wellington Management Group LLP
- Deerfield Management Company L.P. Series C
- Adage Capital Partners GP L.L.C.
- Walleye Capital LLC
- Blue Owl Capital Holdings LP
- Nuveen Asset Management LLC
Within the last year, company insiders that have sold Disc Medicine company stock include:
- Venture Fund X LP Atlas (Major Shareholder)
- Holdings A/S Novo (Major Shareholder)
- Kevin Bitterman (Director)
- Orbimed Advisors Llc (Director)
- Mona Ashiya (Director)
- John D Quisel (CEO)
- Jean M Franchi (CFO)
- Pamela Stephenson (Insider)
Learn More investors selling Disc Medicine stock.
Which institutional investors are buying Disc Medicine stock?
During the previous quarter, IRON stock was purchased by institutional investors including:
- FMR LLC
- Janus Henderson Group PLC
- Price T Rowe Associates Inc. MD
- Raymond James Financial Inc.
- Raymond James Financial Inc.
- Renaissance Technologies LLC
- Dimensional Fund Advisors LP
- D. E. Shaw & Co. Inc.